Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mucus viscosity in the respiratory tract refers to the thickness and flow properties of mucus, a viscoelastic gel that lines and protects airway surfaces. It is determined primarily by water and mucin content. Optimal viscosity is essential for mucociliary clearance. Increased viscosity, often due to increased mucin concentration and decreased water content, is a key feature of several respiratory diseases, leading to airway obstruction and infection. Therapeutic strategies aim to reduce viscosity through hydration, mucolytics, or modulation of ion transport.
Varies depending on the drug; hydrating agents increase water content, mucolytics break down disulfide bonds in mucins, CFTR modulators correct defective chloride transport.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mucus Viscosity in the Respiratory Tract.